Studying Interferon Overactivity in Lupus, Systemic Sclerosis and Related Immune Diseases
Studies blood immune responses in people with autoimmune diseases or interferonopathies.
Plain-language title generated from the registry record
Registry title: Investigation of Type I Interferon Excess in Patients With Systemic Autoimmune Diseases and Genetic Type I Interferonopathies
Key facts
- Where
- Bron, Lyon, and Oullins, FranceSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 6 and 60 years old?
Source: NCT07837986, who can take part
Where in France
- Hôpital Femme Mère EnfantBron, FranceNo longer taking part
- Hopital Edouard HerriotLyon, FranceNo longer taking part
- Centre Hospitalier Lyon SudOullins, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Hospices Civils de Lyon
- Trial code
- NCT07837986
- Record updated
- 24 September 2026
- Original description
Systemic autoimmune diseases associated with type I interferon (IFN-I) dysregulation, such as systemic lupus erythematosus, systemic sclerosis, myositis, and mixed or undifferentiated connective tissue diseases, and genetic type 1 interferonopathies are characterized by chronic and excession IFN-I signaling and production contributing to disease pathogenesis. Aberrant IFN-I production can be triggered through the activation of multiple signaling pathways, particularly those involving intracellular and extracellular RNA and DNA sensing receptors.Read full original descriptionShow less
Type I Interferon Excess in Autoimmune Diseases and Genetic Type I Interferonopathies
Systemic autoimmune diseases associated with type I interferon (IFN-I) dysregulation, such as systemic lupus erythematosus, systemic sclerosis, myositis, and mixed or undifferentiated connective tissue diseases, and genetic type 1 interferonopathies are characterized by chronic and excession IFN-I signaling and production contributing to disease pathogenesis. Aberrant IFN-I production can be triggered through the activation of multiple signaling pathways, particularly those involving intracellular and extracellular RNA and DNA sensing receptors.
We hypothesize that excessive IFN-I production results from an increased tonic activation state of nucleic acid sensors and/or an enhanced responsiveness of these sensors to endogenous nucleic acids, thereby sustaining pathological IFN-I signaling and chronic inflammation.
The aim of this study is to characterize the type I interferon (IFN-I) response, defined by both the IFN-I gene signature and plasma IFN-α levels, following stimulation with a panel of ligands specific for DNA- and RNA-sensing pathways.
Inclusion: Patient; Patient followed at the Hospices Civils de Lyon (HCL) for their disease; Patient aged over 6 years and under 60 years; Body weight ≥ 25 kg; Patient with a confirmed diagnosis of; Systemic lupus erythematosus; Myositis, histologically confirmed or not; Systemic sclerosis,; Mixed connective tissue disease, according to the Sharp or Kasukawa criteria Undifferentiated connective tissue disease, according to the criteria proposed by Mosca et al; Genetically confirmed monogenic lupus or monogenic interferonopathy; Patient, parents, or legal guardians informed about the study and having signed the informed consent form; Healthy Volunteer Participants; Subjects aged over 6 years and under 60 years; Body weight greater than or equal to 25 kg; Participants, parents, or legal guardians who have been informed about the study and have provided written informed consent.
Exclusion: documented infection or symptoms consistent with a bacterial or viral infection within 2 weeks prior to sampling; Subjects currently participating in an interventional drug study; Vaccination within 1 month prior to sampling; Individuals receiving psychiatric care; Documented infection or symptoms consistent with a bacterial or viral infection occurring within 2 weeks prior to sample collection; Vaccination within 1 month prior to sample collection; Individuals receiving psychiatric care; Participant with a long-term chronic disease (ALD) or any chronic medical condition; History of neoplasia (< 5 years) or ongoing neoplastic disease; Patient; Pregnant, parturient, or breastfeeding women; Individuals deprived of liberty by judicial or administrative decision; Individuals admitted to a healthcare or social care institution for reasons other than participation in the research; Adults subject to a legal protection measure; Individuals not affiliated with a social security scheme or not covered by an equivalent health insurance system; Healthy Volunteer Participants; Participant with a primary immunodeficiency; Pregnant, parturient, or breastfeeding women; Individuals deprived of liberty by a judicial or administrative decision; Individuals admitted to a health or social care institution for purposes other than participation in research; Adults subject to a legal protection measure (guardianship or curatorship); Individuals not affiliated with a social security system or not benefiting from an equivalent health insurance scheme.